Targeting Location and Pharmacokinetics of HAb25 Monoclonal Antiboby against Primary Hepatocellular Carcinoma in Human Body
Hu Chuanmin;Liu Yangfang;Sui Yanfang and Liu Chenggang(Department of pathology,4th Military Medical University,Xi'an 710032)
The targeting location and pharmacokinetics of 131labeled HAb25 McAb against primaryhepatocelluler(PHC)carcinoma were investigated in human body. Five patientS with PHC wereadministrated i.v.with a mean dosage of 148 MBq/ling 131I-HAb25. Dynamic observations showedthat four of the PatientS had POsitve scans(80%)and the optimum imaging time was 72 hours afteradministration.The mean tumor/liver ratioes were 2.051 0.42,3.73±0.34 and 2.75±0.72 after 48,72and 96 hours of i.v.administration of the labeled McAb.Blood radioactivities were associatedpredominantly with plasma rather than cellular elements.The urinary excretion of radioactivity wasabout 50% of the injected dosage in the first 28 hours.These resultS revealed that HAb25 McAb wasable to target to PHC tissues in human body and the 131I-HAb25 conjugate was unstablhed bydeiodination in vivo.